Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD+ -dependent deacetylases

Oncogene

Volumn 34, Issue 6, 2015, Pages 798-804

  Yeung, F ^a   Ramsey, C S ^a   Popko Scibor, A E ^a   Allison, D F ^a   Gray, L G ^a   Shin, M ^a   Kumar, M ^a   Li, D ^a   McCubrey, J A ^b   Mayo, M W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRT1 PROTEIN, HUMAN; SIRT2 PROTEIN, HUMAN; SIRTUIN 1; SIRTUIN 2;

ACETYLATION; BIOSYNTHESIS; CELL LINE; CELL NUCLEUS; GENETICS; GENOMIC INSTABILITY; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION;

ACETYLATION; CELL LINE; CELL NUCLEUS; GENOMIC INSTABILITY; HUMANS; MAP KINASE KINASE 1; NAD; NEOPLASMS; PHOSPHORYLATION; SIRTUIN 1; SIRTUIN 2;

EID: 84896690531     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.39     Document Type: Article

References (26)

1. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012; 92: 689-737.
2. Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010; 661: 3-38.
3. Duffy A, Kummar S. Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Target Oncol 2009; 4: 267-273.
4. Huang P, Han J, Hui L. MAPK signaling in inflammation-associated cancer development. Protein Cell 2010; 1: 218-226.
5. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310.
6. Lawrence MC, McGlynn K, Shao C, Duan L, Naziruddin B, Levy MF et al. Chromatin-bound mitogen-activated protein kinases transmit dynamic signals in transcription complexes in ß-cells. Proc Natl Acad Sci USA 2008; 105: 13315-13320.
7. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800.
8. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci USA 2000; 97: 5807-5811.
9. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, Starai VJ et al. A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci USA 2000; 97: 6658-6663.
10. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010; 5: 253-295.
11. Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 2010; 35: 669-675.
12. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer?. Nat Rev Cancer 2009; 9: 123-128.
13. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor?. Int J Biol Sci 2009; 5: 147-152.
14. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26: 5489-5504.
15. Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011; 20: 487-499.
16. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14: 312-323.
17. Li M, Luo R, Chen J, Cao Y, Lu J, He J et al. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellularcarcinoma. J Transl Med 2011; 9: 5.
18. Xiao X, Cai M, Chen J, Guan X, Kung H, Zeng Y et al. High expression of p300 in human breast cancer correlates with tumor recurrence and predicts adverse prognosis. Chin J Cancer Res 2011; 23: 201-207.
19. Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H et al. A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene 2000; 19: 526-536.
20. Giroux S, Tremblay M, Bernard D, Cardin-Girard JF, Aubry S, Larouche L et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 1999; 9: 369-372.
21. Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O et al. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol 2009; 16: 294-303.
22. Park ER, Eblen ST, Catling AD. MEK1 activation by PAK: a novel mechanism. Cell Signal 2007; 19: 1488-1496.
23. Resing KA, Mansour SJ, Hermann AS, Johnson RS, Candia JM, Fukasawa K et al. Determination of v-Mos-catalyzed phosphorylation sites and autophosphorylation sites on MAP kinase kinase by ESI/MS. Biochemistry 1995; 34: 2610-2620.
24. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-2380.
25. Allison DF, Wamsley JJ, Kumar M, Li D, Gray LG, Hart GW et al. Modification of RelA by O-linked N-acetylglucosamine links glucose metabolism to NFkappaB acetylation and transcription. Proc Natl Acad Sci USA 2012; 109: 16888-16893.
26. Bajpe PK, Prahallad A, Horlings H, Nagtegaal I, Beijersbergen R, Bernards R. A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene 2015; 34: 531-536.